Story perspectives

AVIM Therapy Achieves Lasting Blood Pressure Control, FDA Designation

9/5/2025

36 7

Summary

Story summary

AVIM therapy provides lasting blood pressure reduction for years without rebound hypertension after deactivation.
It targets uncontrolled hypertension patients needing a pacemaker, impacting over 750,000 annually.
The FDA awarded AVIM therapy Breakthrough Device Designation for high cardiovascular risk patients.
Pilot study MODERATO II showed 8.1 mmHg reduction in 24-hour ambulatory systolic blood pressure.
Long-term follow-up indicated sustained 8.9 mmHg reduction over 3.6 years.

1 of 1

Story summary

AVIM therapy provides lasting blood pressure reduction for years without rebound hypertension after deactivation.
It targets uncontrolled hypertension patients needing a pacemaker, impacting over 750,000 annually.
The FDA awarded AVIM therapy Breakthrough Device Designation for high cardiovascular risk patients.
Pilot study MODERATO II showed 8.1 mmHg reduction in 24-hour ambulatory systolic blood pressure.
Long-term follow-up indicated sustained 8.9 mmHg reduction over 3.6 years.